Business Wire

NY-ECOVADIS

13.7.2022 09:02:11 CEST | Business Wire | Press release

Share
EcoVadis Accelerates Sustainability Intelligence Capabilities with Acquisition of ecotrek

EcoVadis , the leading provider of globally trusted business sustainability ratings, today announced the acquisition of ecotrek , a sustainability data mining company. The company’s automated sustainability data collection, scanning, and analysis capabilities will complement EcoVadis’ portfolio of solutions by enhancing technical capabilities, improving customer experience, and expanding visibility with robust information about trading partners, thus accelerating the pace of its global scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005172/en/

With over 5 million company profiles already in its database, ecotrek’s sustainability data mining (SDM) capabilities make it possible to automate the gathering and integration of sustainability data into business processes. This gives EcoVadis unmatched access to company-specific insights to understand environmental, social and ethical risk and opportunity, providing even faster and more robust risk visibility for organizations across the entire supply chain.

“The acquisition of ecotrek strengthens our position as the optimal choice for companies to drive sustainability impact at scale across their value chains. We welcome ecotrek’s entrepreneurial team, technology and expertise into our purpose and culture,” said Pierre-François Thaler, co-CEO at EcoVadis. “This is an important step forward as we ramp up our investment in technology and sustainability intelligence capabilities that we are excited to bring to our global customer base.”

ecotrek’s SDM expands upon EcoVadis’ technical capabilities with automated data collection, scanning, analysis, and classification of a company’s sustainability information. This enables EcoVadis to provide even smarter and faster predictive intelligence to optimize sustainability risk management strategies. It also enables EcoVadis to enhance the quality and experience in its ratings while boosting process efficiency for improving the engagement journey with value chain partners. The combined product suite will provide an end-to-end offering from risk classification and monitoring to supplier sustainability performance improvement.

“We shaped and validated our technology around a deep and growing market need for easing and accelerating sustainability insights. EcoVadis is the ideal partner to advance our mission to help companies deploy sustainable procurement at a global scale,” said Rena Kleine, Co-CEO at ecotrek. "By joining forces with EcoVadis, our customers will realize huge benefits in product growth, ability to scale and enable them to integrate sustainability into their procurement processes quickly for maximum impact.”

In light of rising regulations, such as the German Supply Chain Act and the imminent European Directive on supply chain due diligence, the combined end-to-end offerings give customers a giant head start over their peers on monitoring and improving their supply chain to be not only compliant with this law, but to thrive in the new responsible business environment.

ecotrek’s four co-founders brought together their backgrounds in software, engineering, and applied science to create the company in 2020. They and their entire team will join the EcoVadis business and merge with the EcoVadis team in Germany. For more details, contact EcoVadis .

About EcoVadis
EcoVadis is a purpose-led company whose mission is to provide globally trusted business sustainability ratings. Businesses of all sizes rely on EcoVadis’ expert intelligence and evidence-based ratings to monitor and improve the sustainability performance of their business and trading partners. Its actionable scorecards, benchmarks, carbon action tools, and insights guide an improvement journey for environmental, social and ethical practices across 200 industry categories and 175 countries. Industry leaders such as Amazon, Johnson & Johnson, L’Oréal, Unilever, LVMH, Salesforce, Bridgestone, BASF and JPMorgan are among the 95,000 businesses that collaborate with EcoVadis to drive resilience, sustainable growth and positive impact worldwide. Learn more on ecovadis.com , Twitter or LinkedIn .

About ecotrek
ecotrek is a sustainability data mining startup focusing on automated supplier monitoring for the entire supply chain based on publicly available data points. Through machine learning enabled data collection & classification, the ecotrek SDM technology assures instant data insights for thousands of suppliers in a few hours, leading to actionable insights and improvement of the overall supply chain sustainability. Learn more on ecotrek.tech or LinkedIn .

Link:

ClickThru

Social Media:

https://www.facebook.com/ecovadis/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye